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ABSTRACT 
The discovery of new substances with proven antimicrobial activity is the current study goal 
of various researchers. Usage of synthetic products has grown considerably in the past few 
years due to processing agility, and capability of going through previous chemical modifica-
tions in order to enhance its biological activity. Widespread careless use of antimicrobials has 
made the number of resistant microorganisms rise significantly, thus demanding more effi-
cient drugs to fight them. One of these synthetic candidates for this purpose is the substance 
2,2-Dimethyl-5-(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-dioxane-4,6-dione (C9H10N4O4), 
aminomethylene derivative from Meldrum's acid. This substance, alone and in association 
with common antibiotics, were evaluated in vitro for antimicrobial activity, and had their min-
imum inhibitory concentration (MIC) towards Staphylococcus aureus ATCC 25923, Esche-
richia coli ATCC 10536 and Pseudomonas aeruginosa ATCC 15442, as well as multire-
sistant strains Escherichia coli 27, Staphylococcus aureus 358 and Pseudomonas aeruginosa 
03 determined. The antimicrobial modulation action tests of the aminoglycosides with 
C9H10N4O4 were performed according to the microdilution method, and resulted in observa-
tion of a positive synergic effect. 
 
Keywords: synthetic products, antimicrobial activity, resistant microorganisms, Escherichia 
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INTRODUCTION 
Staphylococcus aureus is a spherical bac-
terium from the Gram-positive cocci group, 
also characterized as being a facultative an-
aerobe pathogen. This microorganism is 
easily found on the skin and mucous mem-
branes of human beings, as well as in other 
mammals and birds. It can cause diseases 
that range from simple infections (pustules, 
furuncles and cellulitis) to more serious ones 
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(pneumonia, meningitis, endocarditis, toxic 
shock syndrome, septicemia, etc.) (Santos et 
al., 2007). It is an important etiological agent 
associated with acquired infections in the 
community and in hospitals, which became a 
paradigm of bacterial infections. Considered 
as one of the main human pathogens, it is no-
table for its high frequency and pathogenici-
ty, which leads to diseases both in immuno-
compromised individuals and in healthy 
ones, and also for the easy intra-hospital dis-
semination associated to resistance to antibi-
otics (Coutinho et al., 2008, 2009). 
The appearance of multiresistant S. aure-
us strains in the last few years, isolated even 
from hospital materials and equipments, con-
stitutes a major problem to infection control 
and antimicrobial therapeutics (Araújo et al., 
2000). Multiresistance in S. aureus results 
from the presence of plasmids which most 
frequently allows for multiresistance trans-
fer, among other factors (Freitas, 2003). 
Escherichia coli takes the form of a ba-
cillus and belongs to the Enterobacteriaceae 
family, being aerobe and facultative anaer-
obe (Murray, 2004). It normally exists in an-
imals (including humans) intestinal tract, and 
exert a benefic effect on the organism, sup-
pressing proliferation of harmful bacteria and 
synthesizing a considerable portion of vita-
mins. Among E. coli strains, however, there 
is a group which is capable of causing dis-
eases in humans, that is collectively called 
enteropathogenic E. coli (EEC) (Silva et al., 
2003). 
Pathogenic lineages of E. coli have been 
evidenced as a primary cause of urinary tract 
infections, neonatal meningitis, hospital-
acquired septicemia, and enteritis in humans. 
Resistance to at least two different antibiot-
ics classes is very common, which restricts 
the available therapeutic options (Schneider 
et al., 2009). 
Pseudomonas aeruginosa is character-
ized by a Gram-negative rod, infecting a 
wide variety of plant and animal hosts (Wu 
et al., 2005). In humans, it is responsible for 
chronic lung infections affecting immuno-
compromised patients and also patients with 
cystic fibrosis (Lyczak et al., 2000). P. aeru-
ginosa is the third main cause of nosocomial 
infections (Bonomo and Szabo, 2006).  
Widespread and careless use of antibiot-
ics has led to a series of problems, among 
them, human ecology unbalance and micro-
bial resistance, demanding a search for more 
efficient drugs to combat them. The devel-
opment of any new antimicrobial drug is ac-
companied by microorganisms resistance, 
and their emergence is a threat to research 
advances (Lyczak et al., 2000). Due to the 
large raise of pathogenic microorganisms re-
sistance to multiple drugs, there is a concern 
on finding new therapeutic alternatives 
(Oliveira et al., 2007). For patients, antimi-
crobial resistance augments morbidity, while 
for health institutions it corresponds to high-
er costs (Dancer, 2001). 
According to Montanari (1995), molecu-
lar modification is the most used method to 
obtain new drugs. It consists, basically, in 
starting with a well characterized molecule, 
with known biological action, as a model or 
prototype, from which new compounds will 
be synthesized. The final product will be 
structurally similar, homolog, or analog, to 
the starting substance. Thus, the pharmaceu-
tical industry is constantly developing re-
search on the correlation of molecular struc-
ture and pharmacological activity of new 
synthetic products (Cechinel Filho and 
Yunes, 1998). 
The synthesis of isolated pure substances 
has become a tool of great importance to the 
development of drugs with enhanced phar-
macological properties, and nowadays the 
use of molecular modeling contributes mark-
edly to the discovery of new drugs, which 
are safer and more efficient. Many heterocy-
clic derivatives of Meldrum acid (2,2-
dimethyl-1,3-dioxane-4,6-dione) have been 
prepared and studied from the synthetic and 
structural point of view (Chen, 1991), but, 
however, its biological properties have not 
received the same attention. 
In order to fill this gap, in this study we 
evaluate the antibacterial and the enhance-
ment of antibiotic effect of 2,2-dimethyl-5-
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(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-
dioxane-4,6-dione (C9H10N4O4) against stan-
dard and multiresistant (clinical origin) 
strains of E. coli, S. aureus and P. aerugino-
sa. 
 
MATERIAL AND METHODS 
Synthesis of compound 
The search for a study to demonstrate the 
biological activity with 5-aminomethylene 
Meldrum´s acid derivatives led to a patent in 
1965 (Sterling Drug, 1966). In addition, dif-
ferent heterocyclic rings were condensed to 
the 5-methoxymethylene Meldrum’s acid in 
order to evaluate their potential biological 
activity as antileishmanicidal, antitrypano-
somal and antiviral (Silva, 2006). In this pa-
per, we choose to synthesize the of com-
pound 2,2-Dimethyl-5-(4H-1,2,4-triazol-4-
ylaminomethylene)-1,3-dioxane-4,6-dione, 
C9H10N4O4, an aminomethylene derivative 
from Meldrum's acid in order to explore it 
biological application. The aminomethylene 
derivative can be obtained by condensation 
of an arylamine with 5-(metoximethylene)-
2,2-dimethyl-1,3-dioxane-4,6-dione generat-
ed in situ from a reaction with trimethyl or-
thoformate (Cassis et al., 1985). A solution 
of Meldrum acid (36 mmol) in thimethyl or-
thoformate (50 mL) was heated under reflux 
for 2 h, then the corresponding arylamine 
(30 mmol) was added. Reflux was kept for 
additional 30 minutes. The material thus 
formed was filtered and washed with metha-
nol. The synthesis can be described by the 
scheme shown in Figure 1. The product of 
this synthesis was the compound 2,2-
dimethyl-5-(4H-1,2,4-triazol-4-ylaminome-
thylene)-1,3-dioxane-4,6-dione, C9H10N4O4, 
a crystalline solid with melting point be-
tween 170 °C and 172 °C (Joussef et al., 
2005). 
 
Bacterial material 
Standard and multiresistant lineages of E. 
coli (E. coli ATCC 10536 and E. coli 27), S. 
aureus (S. aureus ATCC 25923 and S. aure-
us 358) and (P. aeruginosa ATCC 15442 
and P. aeruginosa 03) were assayed; the re-
sistance profile is shown in Table 1. All line-
ages were kept in Hear Infusion Agar (HIA, 
Difco Laboratories Inc.). Before the essays 
were carried out, lineages were cultivated at 
37 °C during 18 h in Brain Hear Infusion 
broth (BHI, DIfco Laboratories Inc.). 
 
 
Figure 1: Synthesis of the compound 2,2-Dimethyl-5-(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-
dioxane-4,6-dione, C9H10N4O4 
 
Table 1: Resistance profile of microorganisms 
Microorganism Origin Resistance Profile 
Escherichia coli 27 Surgical wound Ast; Ax; Amp; Ami; Amox; Ca; Can; Caz; Cip; Cfc; Cf; Clo; Im; Szt; Tet; Tob 
Staphylococcus aureus 358 Surgical wound Ami; But; Can; Gen; Neo; Net Oxa; Para; Sis; Tob;
Pseudomonas aeruginosa 03 Urine culture Com; Ctz; Im; Cip; Ptz; Lev; Mer; Ami 
Ast – Aztreonam; Ax – Amoxicillin; Amp – Ampicillin; Ami – Amikacin; Amox – Amoxicillin; But – Butirosina; Ca – Cefadroxil; 
Can – Kanamycin; Caz – Ceftazidime; Cip – Ciprofloxacin; Cfc – Cefaclor; Cf – Cephalothin; Clo – Chloramphenicol; Gen – 
Gentamicin; Im – Imipenem; Neo – Neomycin; Oxa – Oxacillin; Para – Paramomicina; Sis – Sisomicin; Szt – Sulfamethoxazole 
and Trimethoprim; Tet – Trimethoprim; Tob – Tobramycin; Com: Cefepime; Ctz: ceftazidima; Ptz: piperacilina-tazobactam; Lev: 
levofloxacin; Mer: meropenen 
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Antimicrobial activity assay 
The initial solution was prepared by dis-
solving 0,01 g of the synthetic compound 
C9H10N4O4 in 1000 mL of DMSO (Merck), 
to result in a stock solution with concentra-
tion 10 mg/mL. This was diluted to 1024 
μg/mL, and successive 1:2 dilutions with dis-
tilled water yielded concentrations from 512 
to 0.5 μg/mL. The compound C9H10N4O4 
was dissolved using dymethilsulfoxide 
(DMSO - Merck, Darmstadt, Alemanha) us-
ing the following proportions: 0.01 g of 
compound dissolved in 1 mL of DMSO, ob-
taining a solution with 10 mg/mL. This solu-
tion was diluted to 1024 μg/mL and sequen-
tially diluted with sterile water in a range 
varying from 512 to 0.5 μg/mL. The micro-
organisms employed in this study were pro-
vided by Instituto Nacional de Controle de 
Qualidade em Saúde (INCQS) from Funda-
ção Oswaldo Cruz, Ministério da Saúde, 
Brasil. The MIC of the synthetic compound 
C9H10N4O4 was determined by the microdi-
lution in broth method, using concentrations 
ranging from 512 to 8 μg/mL. Previously 
standardized bacterial suspensions were di-
luted in 1:10 proportion with BHI broth to 
yield a final concentration of 105 cells/mL 
(NCCLS, 2003). This method uses small 
volumes of medium (BHI 10 %) and sample 
(C9H10N4O4) distributed in cavities of sterile 
microplates. Sample was prepared in dou-
bled concentration (1024 μg/mL) in relation 
to the defined initial concentration 
(512 μg/mL) with 100 μL volume, and then 
diluted 1:1 serially in BHI 10 %. Using 
100 μL of culture medium per cavity, bacte-
rial suspension was diluted at 1:10 propor-
tion. Negative, positive (medium + microor-
ganism), and inhibition controls were used 
with the culture medium, in concentrations 
ranging from 512 to 8 μg/mL. The filled 
plates were incubated at 35 °C (±2 °C) for 
24 h (Javadpour et al., 1996). A sodium resa-
zurine indicator solution was prepared with 
sterile distilled water (0.01 % w/v) in order 
to determine the MIC of solutions toward 
standard bacterial lineages. After incubation, 
20 μL of the indicator solution was added to 
each cavity, and 1 hour later, under room 
temperature, results were read. A color 
change from blue to pink is due to resazurine 
reduction and indicates that bacterial growth 
has occurred (Palomino et al., 2002). The 
MIC can thus be verified, which is defined 
as the smallest drug concentration capable of 
inhibiting bacterial growth, evidenced by the 
unaltered blue color. The assessment of 
C9H10N4O4 as a possible modulator of anti-
biotic action was done by determining the 
MIC of antibiotics from the aminoglycoside 
group (amikacin, gentamicin e neomycin), 
with and without that substance, in sterile 
microplates. Aminoglycosides concentra-
tions ranged from 2500 to 2.5 μg/ml. The 
C9H10N4O4 solution was added to BHI 10 % 
broth with subinhibitory concentrations, ob-
tained after the MIC assessment, whereas for 
the modulation test, an 8 fold concentration 
reduction (MIC/8) was employed. Antibiot-
ics solutions were prepared in doubled con-
centration (5000 μg/ml), relative to the initial 
one, with sterile distilled water. In each cavi-
ty of the sterile microplate there were 100 μl 
of the culture medium and the diluted (1:10) 
bacterial suspension. The controls used for 
MIC assessment of C9H10N4O4 were the 
same as the ones used for modulation tests 
(Sato et al., 2004). The filled microplates 
were incubated at 35 °C (±2 °C) for 24 h, 
then reading was performed using the resaz-
urine indicator solution, as previously de-
scribed for the MIC assessment. 
 
RESULTS AND DISCUSSION 
Antimicrobials association is still studied 
due to the possibility of suppressing the ap-
pearance of resistant mutants, and producing 
an in vivo synergic effect. An attempt to 
maintain current antimicrobials active could 
be successful by combining them with other 
substances, presenting a therapeutic option to 
treat infections by S. aureus and other patho-
gens, regarding the growing cases of multi-
ple resistance (Maia et al., 2009). 
The MIC assessment test using the sub-
stance C9H10N4O4 indicated that the MIC is 
higher than 1024 μg/ml. According with 
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Houghton et al. (2007), this result indicates 
that the compound does not present a clini-
cally relevant antibiotic activity.  
In the modulation of antibiotic-activity 
test with aminoglycosides it was observed 
that, in relation to Escherichia coli 27, 
C9H10N4O4 presented a synergism with ami-
kacin, reducing the inhibitory concentration 
from 19.5 to 4.9 μg/mL; whereas no noticea-
ble effect was observed with gentamicin and 
neomycin. In relation to Staphylococcus au-
reus 358, C9H10N4O4 presented synergism 
with amikacin, gentamicin and neomycin, 
reducing the inhibitory concentration from 
19.5 to 2.4 μg/mL, 9.8 to 2.4 μg/mL and 
312.5 to 78.125 μg/ml, respectively. With re-
spect to Pseudomonas aeruginosa 03, 
C9H10N4O4 showed synergy only with gen-
tamicin, decreasing the inhibitory concentra-
tion from 156.2 to 39.1 μg/mL (Table 2). 
These results express the same mechanisms 
of action described by Bolla et al. (2011), 
that reports that these synergism is due the 
interaction with the bacterial cell membrane 
or with the lipopolysacharide barrier (LPS), 
enhancing the antibiotic influx, increasing by 
this way the intracellular concentration, or 
inhibiting the antibiotic efflux due the activi-
ty as a blocker of efflux pump (BEP). 
 
Table 2: MIC values (g/mL) of aminoglycosides 
in the absence and presence of the compound 
C9H10N4O4 in multiresistant strains 
 C9H10N4O4 + antibiotic 
antibiotic 
alone 
Escherichia coli 27 
Amikacin 4.9 (S) 19.5 (I) 
Gentamicin 4.9 (R) 4.9 (R) 
Neomycin 1250 (R) 1250 (R) 
Staphylococcus aureus 358 
Amikacin 2.4 (S) 19.5 (I) 
Gentamicin 2.4 (S) 9.8 (R) 
Neomycin 78.1 (R) 312.5 (R) 
Pseudomonas aeruginosa 03 
Amikacin 78.1 (R) 78.1 (R) 
Gentamicin 39.1 (R) 156.2 (R) 
Neomycin 1250 (R) 1250 (R) 
MIC – Minimum Inhibitory Concentration; S – Sensitivity;  
I – intermediary resistance; R – Resistance. 
 
Combination of antibiotics with laborato-
ry synthesized isolated substances could 
serve as a therapeutic option for the treat-
ment of infections caused by S. aureus, E. 
coli , P. aeruginosa and other pathogens, as 
well as an important approach to diminish 
multiple resistance. 
Several compounds, as natural or syn-
thetic, had demonstrated the capacity to 
modulate the antibiotic activity. Phenotia-
zines, in a general form, are capable to inhib-
it the bacterial efflux systems, enhancing the 
antibiotic activity. This activity was demon-
strated by Chlorpromazine and thioridazine 
against several multiresistant bacteria (Am-
aral et al., 2010). As the phenotiazines, natu-
ral products can enhance the antibiotic ac-
tivity inhibiting the bacterial efflux system, 
but also affecting the fluidity of the plasmat-
ic membrane. Natural products as flavonoids 
(quercetin, isoquercetin, Rutin) (Veras et al., 
2011; Araruna et al., 2012), alkaloids (Pilo-
carpine) (Araruna et al., 2012), terpenes (
bisabolol) (Santos et al., 2011) had demon-
strated this activity due the cited mecha-
nisms. Both natural or synthetic compounds, 
modifying the antibiotic activity, can modify 
also the phenotype of the bacterial strains, 
reversing the resistant and intermediary phe-
notype to the sensitivity phenotype, as 
demonstrated by the compound C9H10N4O4 
against the E. coli, S. aureus and P. aeru-
ginosa strains. 
 
CONCLUSIONS 
According to the results obtained, it can 
be seen that the organic compound studied in 
this paper presents a modulator effect on an-
timicrobial activity, fulfilling expectations 
and providing a possible alternative in future 
therapeutics. In particular, it was shown that 
C9H10N4O4 presents antibiotic activity 
against Escherichia coli, Staphylococcus au-
reus and Pseudomonas aeruginosa. 
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